Lan, Yanfang Zhao, Jiahui Zhao, Fangrui Li, Juanjuan Li, Xiangpan
Published in
Frontiers in Oncology
Breast cancer remains one of the predominant malignancies worldwide. In the context of inoperable advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer, systemic management primarily relies on HER2-targeting monoclonal antibodies. With the successful development of anti-HER2 antibody-drug conjugates (ADCs), t...
Guarneri, Valentina; Coelho, Jose Luis Passos; Duhoux, Francois P.; Egle, Daniel; Garcia-Saenz, Jose angel; Penault-Llorca, Frederique; Selander, Katri; Wildiers, Hans; 38568; Zaman, Khalil; Laeis, Petra;
...
Trastuzumab deruxtecan (T-DXd) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (mBC). Results on T-DXd treatment in HER2-low mBC have so far been limited to clinical trials. DESTINY-Breast Respond HER2-low Europe (NCT05945732) is a multi-center, multi-country, observational, prospective,...
Pearson, J Khan, A Bhogal, T Wong, H Law, A Mills, S Santamaria, N Bishop, J Cliff, J Errington, D
...
Published in
ESMO open
Trastuzumab deruxtecan (T-DXd) has demonstrated efficacy in patients with brain metastasis (BM), a group historically with poor outcomes. The prevalence of BMs in patients commencing T-DXd is currently unknown. No direct comparisons have been made of the activity of T-DXd in patients with active BM versus those with extracranial progression alone. ...
Botticelli, Andrea Caputo, Roberta Scagnoli, Simone Pisegna, Simona De Laurentiis, Michelino Curigliano, Giuseppe Lambertini, Matteo Pantano, Francesco Palazzo, Antonella Paris, Ida
...
Published in
The oncologist
Trastuzumab deruxtecan (T-DXd) demonstrated unprecedented efficacy in patients with pretreated HER2+ metastatic breast cancer (mBC). However, few data are available about its efficacy in routine clinical practice. In this multicenter retrospective study, we examined effectiveness and safety of T-DXd in a real-world population. Clinico-pathological ...
Ji, Chenchen Li, Feng Yuan, Yang Zhang, Huiqiang Bian, Li Zhang, Shaohua Wang, Tao Li, Jianbin Jiang, Zefei
Published in
The oncologist
Antibody-drug conjugates (ADCs) have been the preferred regimens for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) after trastuzumab. Unfortunately, there is little data showing which ADCs should be chosen for those patients whose treatment with tyrosine kinase inhibitors (TKIs) failed. This study aims to a...
Chitkara, Akshit Bakhtiar, Muhammad Sahin, Ibrahim Hsu, Dennis Zhang, Janie Anamika, Fnu Mahnoor, Mahnoor Ahmed, Rabeea Gholami, Sepideh Saeed, Anwaar
...
Recent trials provide evidence that HER2 is a potential new target for patients with colorectal cancer. While HER2-positive tumors do not show a very encouraging response to anti-HER2-positive agents like trastuzumab alone, promising results have been observed when combined with other synergistically acting tyrosine kinase inhibitors (TKIs). Our me...
Rainone, Michael Kasparian, Saro Nguyen, Tina Talwar, Neel Yuan, Yuan Mei, Matthew Mortimer, Joanne E Waisman, James R Patel, Niki Pullarkat, Vinod
...
Published in
The oncologist
Trastuzumab emtansine and trastuzumab deruxtecan are widely used in breast cancer and other solid tumor malignancies. Thrombocytopenia is a common adverse event associated with the use of these agents that can lead to a treatment delay, reduction in dose intensity, and discontinuation. The role of thrombopoietin receptor agonists (TPO-RA) remains u...
Henning, Jan-Willem Brezden-Masley, Christine Gelmon, Karen Chia, Stephen Shapera, Shane McInnis, Micheal Rayson, Daniel Asselah, Jamil
Published in
Current oncology (Toronto, Ont.)
Ongoing advances in precision cancer therapy have increased the number of molecularly targeted and immuno-oncology agents for a variety of cancers, many of which have been associated with a risk of pulmonary complications, among the most concerning being drug-induced interstitial lung disease/pneumonitis (DI-ILD). As the number of patients undergoi...
Soares, L R Vilbert, M Rosa, V D L Oliveira, J L Deus, M M Freitas-Junior, R
Published in
ESMO open
Trastuzumab deruxtecan (T-DXd) has been shown to benefit progression-free survival and overall survival in patients with metastatic breast cancer (mBC) after progression on ≥1 human epidermal growth factor receptor 2 (HER2)-targeted therapies. However, interstitial lung disease (ILD) and cardiotoxicity are the most significant toxicities associated...
Curigliano, G Dunton, K Rosenlund, M Janek, M Cathcart, J Liu, Y Fasching, P A Iwata, H
Published in
Annals of oncology : official journal of the European Society for Medical Oncology
In the DESTINY-Breast03 clinical trial, trastuzumab deruxtecan (T-DXd) showed superior progression-free survival and overall survival versus trastuzumab emtansine (T-DM1) and manageable safety in patients with human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer. Here, patient-reported outcomes (PROs) are report...
